Dendritic Cell Transfected with Secondary Lymphoid-Tissue Chemokine and/or Interleukin-2 Gene-Enhanced Cytotoxicity of T-Lymphocyte in Human Bladder Tumor Cell S In Vitro

REFERENCES

• Zhong, H.; Shurin, M.R.; Han, B. Optimizing dendritic cell-based immunotherapy for cancer. Exp Rev Vaccines 2007, 6, 333–345.
   PubMed Web of Science ®Google Scholar
• Nabekura, T.; Nagasawa, T.; Nakauchi, H. An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2.Cancer Immunol Immunother 2007.
   PubMed Web of Science ®Google Scholar
• Chang, H.W.; Chow, Y.H.; Chong, P.; Sia, C. The cross-regulatory relationship between human dendritic and regulatory T cells and its role in type 1 diabetes mellitus. Rev Diabet Stud 2007, 4, 68–76.
   PubMedGoogle Scholar
• van der Velden, A.M.; Claessen, A.M.; van Velzen-Blad, H. Development of T cell–mediated immunity after autologous stem cell transplantation: prolonged impairment of antigen-stimulated production of gamma-interferon. Bone Marrow Transplant 2007, 40, 261–266.
   PubMed Web of Science ®Google Scholar
• Liang, C.M.; Ye, S.L.; Zhong, C.P.; Zheng, N. More than chemotaxis: a new anti-tumor DC vaccine modified by rAAV2-SLC. Mol Immunol 2007, 44, 3797–3804.
   PubMed Web of Science ®Google Scholar
• Tian, J.Q.; Wang, Z.P.; Rodriguez, R. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor–related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma. Urology 2006, 67, 1093–1098.
   PubMed Web of Science ®Google Scholar
• Carmichael, J.; DeGraff, W.G.; Gazdar, A.F.; Minna, J.D.; Mitchell, J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay:assessment of chemosensitivity testing. Cancer Res 1987, 47, 936–942.
   PubMed Web of Science ®Google Scholar
• Beharier, O.; Etzion, Y.; Katz, A.; Friedman, H.; Tenbosh, N.; Zacharish, S.; Bereza, S.; Goshen, U.; Moran, A. Cross-talk between L-type calcium channels and ZnT-1, a new player in rate-dependent cardiac electrical remodeling. Cell Calcium 2007, 42, 71–82.
   PubMed Web of Science ®Google Scholar
• Maitre, N.; Brown, J.M.; Demcheva, M. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Clin Cancer Res 1999, 5, 1173–1182.
   PubMed Web of Science ®Google Scholar
• Lee, J.; Lee, H.-J.; Park, J.-D. Anti-cancer activity of highly purified sulfur in immortalized and malignant human oral keratinocytes. Toxicol In Vitro 2007.
   Web of Science ®Google Scholar
• Kim, J.W.; Ferris, R.L.; Whiteside, T.L.; Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. J Clin Cancer Res 2005, 11, 7901–7910.
   Web of Science ®Google Scholar
• Cavanagh, L.L.; Von Andrian, U.H. Travellers in many guises: the origins and destinations of dendritic cells. Immunol Cell Biol 2002, 80, 448–462.
   PubMed Web of Science ®Google Scholar
• Gabrilovich, D.I.; Chen, H.L.; Girgis, K.R.; Cunningham, H.T.; Meny, G.M.; Nadaf, S.; Kavanaugh, D.; Carbone, D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2, 1096–1103.
   PubMed Web of Science ®Google Scholar
• Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 392, 245–252.
   PubMed Web of Science ®Google Scholar
• Inaba, K.; Witmer-Pack, M.; Inaba, M.; Hathcock, K.S.; Sakuta, H.; Azuma, M.; Yagita, H.; Okumura, K.; Linsley, P.S.; Ikehara, S.; The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 1994, 180, 1849–1860.
   PubMed Web of Science ®Google Scholar
• Waldmann, T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006, 6, 595–601.
   PubMed Web of Science ®Google Scholar
• Fyfe, G.; Fisher, R.I.; Rosenberg, S.A.; Sznol, M.; Parkinson, D.R.; Louie, A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13, 688.
   PubMed Web of Science ®Google Scholar
• Sharma, S.; Stolina, M.; Luo, J.; Strieter, R.M.; Burdick, M.; Zhu, L.X.; Batra, R.K.; Dubinett, S.M. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000, 164, 4558–4563.
   PubMed Web of Science ®Google Scholar
• Sharma, S.; Yang, S.K. SLC/CCL21-mediated anti-tumor responses require IFNγ, MIG/CXCL9, and IP-10/CXCL10. Mol Cancer 2003, 15, 22.
   Google Scholar
• Kirk, C.J.; Hartigan-O'Connor, D.; Nickoloff, B.J.; Chamberlain, J.S.; Giedlin, M.; Aakerman, L.; T cell–dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell–based immunotherapy. Cancer Res 2001, 61, 2062–2070.
   PubMed Web of Science ®Google Scholar
• Hao, S.; Moyana, T.; Xiang, J. Cancer immunotherapy by exosome-based vaccines. Cancer Biother Radiopharm 2007, 22, 692–703.
   PubMed Web of Science ®Google Scholar
• Li, N.; Qin, H.; Li, X.; Zhou, C. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor-associated antigen gene-modified tumor cell and blockade of B7-H1. J Clin Immunol 2007, 27, 117–130.
   PubMed Web of Science ®Google Scholar
• Liang, C.M.; Zhong, C.P.; Sun, R.X. Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J Virol 2007, 81, 9502–9511.
   PubMed Web of Science ®Google Scholar
• Van Nimwegen, M.J.; Verkoeijen, S.; Kuppen, P.J. An improved method to study NK-independent mechanisms of MTLn3 breast cancer lung metastasis, Clin Exp Metast 2007, 24, 379–387.
   PubMed Web of Science ®Google Scholar
• Schenck, M.; Börgermann, C.; Jäager, T. Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a, and erythropoietin-beta. Urologe A 2007, 46, 528–534.
   PubMedGoogle Scholar
• Margolin, K.A. Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000, 27, 194–203.
   PubMed Web of Science ®Google Scholar
• Atkins, M.B.; Lotze, M.T.; Dutcher, J.P.; Fisher, R.I.; Weiss, G.; Margolin, K.; High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17, 2105–2116.
   PubMed Web of Science ®Google Scholar
• Rosenberg, S.A.; Yang, J.C.; Schwartzentruber, D.J.; Hwu, P.; Marincola, F.M. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4, 321–327.
   PubMed Web of Science ®Google Scholar
• Matsuyoshi, H.; Senju, S.; Hirata, S. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination. J Immunol 2004, 172, 776–786.
   PubMed Web of Science ®Google Scholar
• Kirk, C. J.; Hartigan-O'Connor, D.; Nickoloff, B.J.; Mule, J. T cell–dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001, 61, 2062.
   PubMed Web of Science ®Google Scholar
• Mahnke, K.; Ring, S.; Johnson, T.S.; Schallenberg, S. Induction of immunosuppressive functions of dendritic cells in vivo by CD4 + CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Eur J Immunol 2007, 37, 2117–2126.
   PubMed Web of Science ®Google Scholar
• Sharma, S.; Stolina, M.; Luo, J.; Secondary lymphoid tissue chemokine mediates T cell–dependent antitumor responses in vivo. J Immunol 2000, 164, 4558–4563.
   PubMed Web of Science ®Google Scholar
• Eo, S.K.; Lee, S.; Kumaraguru, U. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands, Vaccine 2001, 19, 4685–4693.
   PubMed Web of Science ®Google Scholar
• He, Y.F.; Zhang, G.M.; Wang, X.H.; Zhang, H. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol 2004, 173, 4919–4928.
   PubMed Web of Science ®Google Scholar
• Abu-Khalaf, M.M.; Wheler, J.; Zerkowski, M.; High expression of the chemokine receptor CCR7 is associated with worse outcome in breast cancer. ASCO Meet Abstr 2005, 23, 9593.
   Google Scholar
• Takeuchi, H.; Fujimoto, A.; Tanaka, M. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 2004, 10, 2351–2358.
   PubMedGoogle Scholar